Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched

MA Holder Theramex Has Plans For More EU Countries

Executive Summary

After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.

You may also be interested in...



Theramex And Alkem’s Enzene Ally On Denosumab

Women’s health specialist Theramex has struck a deal with Alkem’s Enzene Biosciences biotech subsidiary to gain rights to Enzene’s proposed denosumab biosimilar version of Prolia in Europe and Australia.

Gedeon Richter Spends Most On Biosimilar R&D

Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.

Ligand Set For Partnership Opportunities After Completing On Pfenex

Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel